# DOK7

## Overview
DOK7 is a gene that encodes the protein docking protein 7, which plays a critical role in neuromuscular synaptogenesis. Docking protein 7 is categorized as an adaptor protein, characterized by its pleckstrin homology (PH) and phosphotyrosine-binding (PTB) domains, which are essential for its function in the neuromuscular junction (NMJ) (Okada2006The). The PH domain facilitates membrane association, while the PTB domain is crucial for binding to phosphorylated tyrosine residues on muscle-specific kinase (MuSK), a key receptor in NMJ formation (Okada2006The; Buyan2016Multiscale). Through these interactions, DOK7 is instrumental in the clustering of acetylcholine receptors, a process vital for effective neuromuscular transmission and muscle contraction (Zhang2022A). Mutations in the DOK7 gene are linked to congenital myasthenic syndromes, underscoring its importance in maintaining neuromuscular health (Vogt2009Germline).

## Structure
The DOK7 protein is composed of 504 amino acids and features several key domains that are crucial for its function. It contains an N-terminal pleckstrin homology (PH) domain and a phosphotyrosine-binding (PTB) domain, both of which are essential for its role in neuromuscular synaptogenesis (Okada2006The). The PH domain is involved in membrane association through interactions with phosphatidylinositol phosphates (PIPs), which are negatively charged lipids. This domain binds to membranes via electrostatic interactions, particularly involving the β1/β2 and β3/β4 loops (Buyan2016Multiscale). The PTB domain binds to phosphorylated tyrosine residues in the muscle-specific kinase (MuSK), facilitating downstream signaling necessary for acetylcholine receptor clustering (Okada2006The; Buyan2016Multiscale).

DOK7 undergoes alternative splicing, resulting in at least two isoforms. Isoform 1 is the full-length protein containing both the PH and PTB domains, while isoform 2 is truncated, retaining the PH domain and part of the PTB domain but lacking critical tyrosine residues necessary for full functionality (Ahsan2017SRSF1). These structural features and splice variants are vital for DOK7's role in neuromuscular junction formation.

## Function
DOK7 encodes docking protein 7, which is essential for neuromuscular synapse formation. In healthy human cells, DOK7 interacts with muscle-specific kinase (MuSK) to facilitate its phosphorylation, a critical step for the clustering of acetylcholine receptors (AChRs) at the neuromuscular junction (NMJ) (Zhang2022A; Okada2006The). This interaction is mediated through DOK7's phosphotyrosine-binding (PTB) domain, which binds to phosphorylated MuSK, and its pleckstrin homology (PH) domain, which helps anchor DOK7 to the plasma membrane (Hallock2010Dok-7; Zhang2022A).

DOK7's role in MuSK activation is crucial for the formation and maintenance of the NMJ, ensuring effective neuromuscular transmission and muscle contraction (Chen2017The; Sugimoto2024Peroxisome). The protein is primarily active in skeletal muscle cells, where it promotes postsynaptic differentiation by recruiting other proteins such as Crk and Crk-L, which are involved in synaptic signaling pathways (Hallock2010Dok-7). Mutations in DOK7 can lead to congenital myasthenic syndromes, characterized by impaired synapse formation and muscle weakness (Zhang2022A; Vogt2009Germline).

## Clinical Significance
Mutations in the DOK7 gene are a significant cause of congenital myasthenic syndromes (CMS), a group of disorders characterized by muscle weakness and fatigue due to impaired neuromuscular transmission. DOK7 mutations account for approximately 15-20% of CMS cases in the UK, with a wide spectrum of mutations, most commonly affecting the C-terminus of the protein (Rodríguez2018The). The most prevalent mutation is c.1124_1127dupTGCC, which is found in about 65% of cases and leads to a truncated protein that disrupts normal interactions necessary for neuromuscular junction stability (Engel2012Current; Nouri2024Clinical).

Clinically, DOK7-related CMS typically presents with limb-girdle weakness, mild ptosis, and facial weakness, although severe bulbar symptoms are rare (Engel1988Congenital; Hantaï2004Congenital). The condition can manifest at various stages, from in utero to early childhood, and ranges from mild static weakness to severe progressive disease with muscle atrophy (Engel2008Congenital). Conventional treatments like pyridostigmine often worsen symptoms, while β2-adrenergic agonists such as salbutamol and ephedrine have shown effectiveness in improving muscle strength and function (Jadhav2019Intrafamilial; Nouri2024Clinical). The phenotypic variability and response to treatment can vary even among individuals with the same genotype, highlighting the complexity of DOK7-related CMS (Jadhav2019Intrafamilial).

## Interactions
DOK7 interacts with several proteins crucial for neuromuscular synapse formation. It is recruited to the muscle-specific kinase (MuSK) receptor upon phosphorylation by Agrin, a protein released by motor neurons. This interaction is mediated through DOK7's pleckstrin homology (PH) and phosphotyrosine-binding (PTB) domains, which bind to phosphorylated MuSK, promoting further phosphorylation and activation of MuSK (Hallock2010Dok-7; Okada2006The).

Phosphorylated DOK7 recruits adapter proteins Crk and Crk-L, which are essential for synaptic differentiation. These interactions are mediated by the SH2 domains of Crk and Crk-L, and their inactivation in muscle results in synaptic defects (Hallock2010Dok-7). DOK7 also interacts with protein kinase CK2, which phosphorylates DOK7 at specific serine residues, influencing its ability to aggregate acetylcholine receptors (AChRs) in myotubes (Herrmann2015Protein).

The PH domain of DOK7 is necessary for its interaction with CK2, and this interaction is significant for synaptic function or signaling at the neuromuscular junctions (Herrmann2015Protein). These interactions highlight DOK7's role in facilitating downstream signaling pathways essential for muscle function.


## References


[1. (Zhang2022A) Shaochuan Zhang, Bisei Ohkawara, Mikako Ito, Zhizhou Huang, Fei Zhao, Tomohiko Nakata, Tomoya Takeuchi, Hidetoshi Sakurai, Hirofumi Komaki, Masayoshi Kamon, Toshiyuki Araki, and Kinji Ohno. A mutation in dok7 in congenital myasthenic syndrome forms aggresome in cultured cells, and reduces dok7 expression and musk phosphorylation in patient-derived ips cells. Human Molecular Genetics, 32(9):1511–1523, December 2022. URL: http://dx.doi.org/10.1093/hmg/ddac306, doi:10.1093/hmg/ddac306. This article has 6 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/ddac306)

[2. (Herrmann2015Protein) Dustin Herrmann, Marion Straubinger, and Said Hashemolhosseini. Protein kinase ck2 interacts at the neuromuscular synapse with rapsyn, rac1, 14-3-3γ, and dok-7 proteins and phosphorylates the latter two. Journal of Biological Chemistry, 290(37):22370–22384, September 2015. URL: http://dx.doi.org/10.1074/jbc.m115.647610, doi:10.1074/jbc.m115.647610. This article has 16 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m115.647610)

[3. (Hallock2010Dok-7) Peter T. Hallock, Chong-Feng Xu, Tae-Ju Park, Thomas A. Neubert, Tom Curran, and Steven J. Burden. Dok-7 regulates neuromuscular synapse formation by recruiting crk and crk-l. Genes &amp; Development, 24(21):2451–2461, November 2010. URL: http://dx.doi.org/10.1101/gad.1977710, doi:10.1101/gad.1977710. This article has 91 citations.](https://doi.org/10.1101/gad.1977710)

[4. (Okada2006The) Kumiko Okada, Akane Inoue, Momoko Okada, Yoji Murata, Shigeru Kakuta, Takafumi Jigami, Sachiko Kubo, Hirokazu Shiraishi, Katsumi Eguchi, Masakatsu Motomura, Tetsu Akiyama, Yoichiro Iwakura, Osamu Higuchi, and Yuji Yamanashi. The muscle protein dok-7 is essential for neuromuscular synaptogenesis. Science, 312(5781):1802–1805, June 2006. URL: http://dx.doi.org/10.1126/science.1127142, doi:10.1126/science.1127142. This article has 348 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1126/science.1127142)

[5. (Engel2008Congenital) Andrew G. Engel. Congenital myasthenic syndromes, pages 285–331. Elsevier, 2008. URL: http://dx.doi.org/10.1016/s0072-9752(07)01510-2, doi:10.1016/s0072-9752(07)01510-2. This article has 11 citations.](https://doi.org/10.1016/s0072-9752(07)01510-2)

[6. (Buyan2016Multiscale) Amanda Buyan, Antreas C. Kalli, and Mark S. P. Sansom. Multiscale simulations suggest a mechanism for the association of the dok7 ph domain with pip-containing membranes. PLOS Computational Biology, 12(7):e1005028, July 2016. URL: http://dx.doi.org/10.1371/journal.pcbi.1005028, doi:10.1371/journal.pcbi.1005028. This article has 24 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1371/journal.pcbi.1005028)

[7. (Ahsan2017SRSF1) Khalid Bin Ahsan, Akio Masuda, Mohammad Alinoor Rahman, Jun-ichi Takeda, Mohammad Nazim, Bisei Ohkawara, Mikako Ito, and Kinji Ohno. Srsf1 suppresses selection of intron-distal 5′ splice site of dok7 intron 4 to generate functional full-length dok-7 protein. Scientific Reports, September 2017. URL: http://dx.doi.org/10.1038/s41598-017-11036-z, doi:10.1038/s41598-017-11036-z. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-017-11036-z)

[8. (Engel2012Current) Andrew G. Engel. Current status of the congenital myasthenic syndromes. Neuromuscular Disorders, 22(2):99–111, February 2012. URL: http://dx.doi.org/10.1016/j.nmd.2011.10.009, doi:10.1016/j.nmd.2011.10.009. This article has 107 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.nmd.2011.10.009)

[9. (Hantaï2004Congenital) Daniel Hantaï, Pascale Richard, Jeanine Koenig, and Bruno Eymard. Congenital myasthenic syndromes. Current Opinion in Neurology, 17(5):539–551, October 2004. URL: http://dx.doi.org/10.1097/00019052-200410000-00004, doi:10.1097/00019052-200410000-00004. This article has 62 citations and is from a peer-reviewed journal.](https://doi.org/10.1097/00019052-200410000-00004)

[10. (Rodríguez2018The) Pedro M. Rodríguez Cruz, Jacqueline Palace, and David Beeson. The neuromuscular junction and wide heterogeneity of congenital myasthenic syndromes. International Journal of Molecular Sciences, 19(6):1677, June 2018. URL: http://dx.doi.org/10.3390/ijms19061677, doi:10.3390/ijms19061677. This article has 82 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms19061677)

[11. (Vogt2009Germline) J Vogt, N V Morgan, T Marton, S Maxwell, B J Harrison, D Beeson, and E R Maher. Germline mutation in dok7 associated with fetal akinesia deformation sequence. Journal of Medical Genetics, 46(5):338–340, March 2009. URL: http://dx.doi.org/10.1136/jmg.2008.065425, doi:10.1136/jmg.2008.065425. This article has 61 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1136/jmg.2008.065425)

[12. (Chen2017The) Gang Chen, Hefen Yu, Lucy Satherley, Catherine Zabkiewicz, Jeyna Resaul, Huishan Zhao, Hu Mu, Xiuyi Zhi, Junqi He, Lin Ye, and Wen G. Jiang. The downstream of tyrosine kinase 7 is reduced in lung cancer and is associated with poor survival of patients with lung cancer. Oncology Reports, 37(5):2695–2701, March 2017. URL: http://dx.doi.org/10.3892/or.2017.5538, doi:10.3892/or.2017.5538. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/or.2017.5538)

13. (Nouri2024Clinical) Clinical and molecular analysis of a novel variant responsive to salbutamol monotherapy during COVID-19 outbreak related to congenital and late-onset of myasthenic syndrome in large kindred. This article has 0 citations.

[14. (Engel1988Congenital) Andrew G. Engel. Congenital myasthenic syndromes. Journal of Child Neurology, 3(4):233–246, October 1988. URL: http://dx.doi.org/10.1177/088307388800300402, doi:10.1177/088307388800300402. This article has 30 citations and is from a peer-reviewed journal.](https://doi.org/10.1177/088307388800300402)

[15. (Jadhav2019Intrafamilial) Trupti Jadhav, Poornima Shah, Purva Keni Karnavat, and Anaita Udwadia Hegde. Intrafamilial variation in clinical manifestations and response to salbutamol in siblings with congenital myasthenic syndrome caused by dok7 mutations. Journal of the International Child Neurology Association, November 2019. URL: http://dx.doi.org/10.17724/jicna.2019.122, doi:10.17724/jicna.2019.122. This article has 0 citations.](https://doi.org/10.17724/jicna.2019.122)

[16. (Sugimoto2024Peroxisome) Takumi Sugimoto, Chihiro Sakamaki, Tokushi Kimura, Takahiro Eguchi, Shinji Miura, and Yasutomi Kamei. Peroxisome proliferator-activated receptor γ coactivator 1α regulates downstream of tyrosine kinase-7 (dok-7) expression important for neuromuscular junction formation. Scientific Reports, January 2024. URL: http://dx.doi.org/10.1038/s41598-024-52198-x, doi:10.1038/s41598-024-52198-x. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-024-52198-x)